AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7036300
Drug: No other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No other treatment (Control)
Trial: 30716200
Drug: Second-line chemotherapy
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line chemotherapy (2L CT)
Trial: 27085870
Drug: Zolpidem (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (12.5 mg at 2300) and Nabilone (3 mg at 0900 and 1800)
Trial: 27085870
Drug: Zolpidem (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (12.5 mg at 2300)
Trial: 22453547
Drug: 7.5% CO(2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% CO(2) inhalation
Trial: 19814838
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein intake (55.9‐61.0 g/d on average)
Trial: 10409598
Drug: High-hormone phase
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-hormone phase (progesterone/estrogen)
Trial: 10409598
Drug: Low-hormone phase
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-hormone phase (placebo)
Trial: 7672489
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin therapy
Trial: 7043728
Drug: Diflunisal 1
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diflunisal 1 g daily
Trial: 29096671
Drug: Reactive focal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive focal drug administration (RFDA) using dihydroartemisinin‐piperaquine (DHAP)
Trial: 26065506
Drug: 1% chloramphenicol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chloramphenicol eye ointment
Trial: 26065506
Drug: 2.5% povidone-iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% povidone-iodine ophthalmic solution
Trial: 23521128
Drug: IT therapy
RxNorm normalized name: Salicylic Acid 2% Topical application Cream [STRI-DEX FRUIT THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT therapy responses
Trial: 20646083
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg of Wheat Extract Oil (WEO)
Trial: 18821119
Drug: 1% pramoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% pramoxine hydrochloride lotion applied twice daily for 4 weeks
Trial: 17892995
Drug: Cangrelor with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cangrelor with half-dose t-PA
Trial: 17892995
Drug: Full-dose t-PA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose t-PA
Trial: 17113442
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg prednisolone intramuscularly immediately after surgery
Trial: 17113442
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg prednisolone and diclofenac intramuscularly immediately after surgery
Trial: 17113442
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline solution (control group)
Trial: 11110934
Drug: Intracoronary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiation therapy (RT)
Trial: 8958363
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg orally daily
Trial: 1526735
Drug: Intravenous epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous epinephrine infusion (1 microgram/hr)
Trial: 25882384
Drug: Combination training
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination training (AT/RT)
Trial: 19317379
Drug: Ramelteon, 8
RxNorm normalized name: Ramelteon, 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon, 8 mg
Trial: 19317379
Drug: Zolpidem, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem, 10 mg (positive control)
Trial: 15554771
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 600 mg/day b.i.d. for 5 days
Trial: 11672449
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy with transdermal oestradiol (50 microg/24 h patch or 1 mg/day gel) combined with oral dihydrogesterone (10 mg/day for 12 days/month, days 19-30).
Trial: 29804377
Drug: LAM and
RxNorm normalized name: Alprazolam and propranolol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM and ADV combination therapy
Trial: 28044367
Drug: 1% anthralin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% anthralin ointment
Trial: 17399814
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of simvastatin daily (n=40)
Trial: 17262124
Drug: Chemical disinfection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemical disinfection (immersion in 100 ppm chloride solution)
Trial: 1301847
Drug: Compound Salvia
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Salvia tablet (CST)
Trial: 3927708
Drug: Aerosolized edetate
RxNorm normalized name: EDETATE
DrugBank: Edetate sodium (DB13404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized edetate sodium plus oral tetracycline twice daily for three months
Trial: 3927708
Drug: Placebo aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo aerosol plus oral tetracycline for three months
Trial: 29721732
Drug: Topical diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diltiazem 2% ointment
Trial: 26496621
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (AndroGel® 1.62%)
Trial: 23568851
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of lecithin before surgery
Trial: 16803913
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (taught oral examination skills)
Trial: 16803913
Drug: E1 (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E1 (initial oral examination)
Trial: 16803913
Drug: E2 (subsequent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 (subsequent oral examination)
Trial: 29244208
Drug: Joint gaming
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint gaming on a tablet
Trial: 23688265
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine (DFO) combined with deferiprone (DFP) at 75 mg/kg/day
Trial: 23688265
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine (DFO) monotherapy at 50-60 mg/kg 12-24 hr/day sc or iv 7 times weekly
Trial: 12714435
Drug: High combined
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High combined antibody response
Trial: 12714435
Drug: High combined
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High combined antibody response (adjusted for age and CHD risk factors)
Trial: 12714435
Drug: Combined antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antibody response
Trial: 12410369
Drug: Acupuncture (AP)
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (AP) treatments
Trial: 12410369
Drug: Placebo acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo acupuncture (AP) treatments
Trial: 10765004
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of octreotide (50 microg every 6 hours) plus intravenous infusion of low-dose insulin (4 units per hour)
Trial: 10765004
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin alone (4 units per hour)
Trial: 1835291
Drug: Theophylline (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (dose titrated to produce serum levels of 10-20 micrograms/mL)
Trial: 24728028
Drug: Interferential current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential current therapy (IFC)
Trial: 16603634
Drug: Daclizumab 1
RxNorm normalized name: daclizumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 1 mg/kg intravenously at weeks 0 and 4
Trial: 16603634
Drug: Daclizumab 2
RxNorm normalized name: daclizumab 25 MG per 5 ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 2 mg/kg intravenously at weeks 0, 2, 4, and 6
Trial: 3896811
Drug: Metoprolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (15 mg I.V. followed by oral administration)
Trial: 22835702
Drug: Synbiotic food
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic food supplement (containing fructo‐oligosaccharides and probiotic strains)
Trial: 22835702
Drug: Synbiotic food
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic food supplement
Trial: 21055143
Drug: Thymopetide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopetide (2 mg/day i.m. for 75 days)
Trial: 15993253
Drug: SSRI antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI antidepressants (specific SSRIs not detailed)
Trial: 15993253
Drug: Discontinued SSRI
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued SSRI treatment
Trial: 15993253
Drug: Baseline patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline patient skepticism about taking an antidepressant
Trial: 10801969
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose zinc supplements
Trial: 10801969
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose antioxidants
Trial: 8719121
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BL) at 3000 lux for 6 days after PSD
Trial: 8719121
Drug: Dim light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim light therapy (DL) at 100 lux for 6 days after PSD
Trial: 1595849
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg pretreatment
Trial: 25234807
Drug: Linezolid therapy
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid therapy (1200 mg per day for 4-6 weeks, then 300-600 mg per day)
Trial: 25234807
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard chemotherapy regimen)
Trial: 17285968
Drug: Endonasal sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endonasal sinus surgery with frontal sinus opened and drained by two pipes of silicone for 6 months plus injection of beclomethasone (Group 2)
Trial: 29635395
Drug: Accelerated Resolution
RxNorm normalized name: Revolution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Resolution Therapy (ART); mean number of sessions received: 3.9 ± 1.1.
Trial: 25676540
Drug: Oral Δ(9)‐THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Δ(9)‐THC (maximum 28 mg/day)
Trial: 21917649
Drug: Celecoxib treatment
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib treatment for 24 months
Trial: 21917649
Drug: Anti-H pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-H pylori treatment for 7 days
Trial: 19687005
Drug: Telemonitoring with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemonitoring with pharmacological treatment for 6 months
Trial: 19687005
Drug: Telemonitoring with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemonitoring with pharmacological treatment for 6 months (per-protocol analysis)
Trial: 15286098
Drug: Ximelagatran 36
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 36 mg twice daily for 8 days
Trial: 15286098
Drug: Digoxin 0.5
RxNorm normalized name: digoxin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.5 mg single oral dose on day 4
Trial: 9701198
Drug: 1.6 mg
RxNorm normalized name: menthol 1.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg riboflavin daily for 12 weeks
Trial: 9701198
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg riboflavin daily for 12 weeks
Trial: 8611450
Drug: Campath‐1H (humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath‐1H (humanized CD52 monoclonal antibody)
Trial: 2285631
Drug: Propionyl carnitine
RxNorm normalized name: glycine propionyl-L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl carnitine (PC) 500 mg three times a day for 30 days
Trial: 21273492
Drug: GLP-1 administration
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 administration during meal
Trial: 21273492
Drug: GLP-1 administration
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 administration during OGTT
Trial: 21273492
Drug: GLP-1 administration
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 administration during hyperglycemic clamps
Trial: 21273492
Drug: GLP-1 administration
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 administration after improved glycemic control
Trial: 20112480
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus music therapy (Group Acup. + M)
Trial: 16636212
Drug: Calcium carbonate,
RxNorm normalized name: calcium carbonate, precipitated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium carbonate, 600 mg twice per day
Trial: 11591548
Drug: Dextromethorphan hydrobromide,
RxNorm normalized name: Dextromethorphan Hydrobromide, 15 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan hydrobromide, 30 mg
Trial: 9334894
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg for > or = 7 weeks
Trial: 8228350
Drug: Single-dose live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose live oral cholera vaccine strain CVD 103-HgR (5 x 10(9) cfu)
Trial: 8228350
Drug: Single-dose live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose live oral cholera vaccine strain CVD 103-HgR
Trial: 10421260
Drug: Postoperative intrahepatic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intrahepatic arterial chemotherapy (2-3 courses with a maximum dose of 80 mg of cisplatin and 10 mg of mitomycin C at 1-month intervals)
Trial: 7570405
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose inhaled steroid (400 micrograms beclomethasone dipropionate) + salmeterol (100 micrograms)
Trial: 7570405
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose inhaled steroid (1000 micrograms beclomethasone dipropionate)
Trial: 6182894
Drug: Lidocaine (trimecain)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (trimecain) administered intravenously and then intramuscularly for a day
Trial: 6182894
Drug: Lidocaine administered
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine administered intramuscularly for 1.8 years
Trial: 23392332
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg i.v. (dexamethasone group, n = 20)
Trial: 19927630
Drug: Amiodarone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone plus irbesartan (150 mg/d)
Trial: 17530099
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose E2/NETA (2 mg E2/1 mg NETA)
Trial: 15167457
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lisinopril (LIS) daily for 4 weeks
Trial: 15167457
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg hydrochlorothiazide (HCT) daily for 4 weeks
Trial: 31397488
Drug: telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telbivudine 600 mg/d oral
Trial: 31397488
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antiviral drugs)
Trial: 26216500
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (40-60 mg/day)
Trial: 26216500
Drug: Intramuscular adrenocorticotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular adrenocorticotropic hormone (40-60 IU/every other day)
Trial: 23137389
Drug: Oral altrenogest
RxNorm normalized name: Altrenogest
DrugBank: Altrenogest (DB11372)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral altrenogest (0.044 mg/kg; Regumate(®) ) for 11 days
Trial: 23137389
Drug: Intravaginal progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravaginal progesterone (1.38 g; CIDR(®) ) for 11 days
Trial: 11032589
Drug: Toremifene 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 40 mg/d
Trial: 11032589
Drug: Toremifene 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 40 mg/d (ER-positive subgroup)
Trial: 11032589
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/d (ER-positive subgroup)
Trial: 1740538
Drug: HCTZ/TRI (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ/TRI (25 mg/50 mg)
Trial: 1740538
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg (Ate-25)
Trial: 1740538
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg (Ate-50)
Trial: 1740538
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg + HCTZ/TRI (Ate-25/HCTZ/TRI)
Trial: 1740538
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg + HCTZ/TRI (Ate-50/HCTZ/TRI)
Trial: 1740538
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg (Ate-25), Atenolol 50 mg (Ate-50), HCTZ/TRI, Ate-25/HCTZ/TRI, Ate-50/HCTZ/TRI
Trial: 1740538
Drug: HCTZ/TRI (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ/TRI (25 mg/50 mg), Ate-25/HCTZ/TRI, Ate-50/HCTZ/TRI
Trial: 6747020
Drug: experimental extended‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental extended‐release capsules
Trial: 6747020
Drug: experimental extended‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental extended‐release tablets
Trial: 31022213
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (40 IU once daily for four weeks)
Trial: 31022213
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline once daily for four weeks)
Trial: 15860827
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral supplementation using 1000 mg calcium with 800 IU cholecalciferol and information leaflet on dietary calcium intake and prevention of falls
Trial: 8017639
Drug: AVP type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP type V1 antagonist (AVPA)
Trial: 8017639
Drug: Enalapril (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (1.25 mg intravenous)
Trial: 8017639
Drug: Enalapril (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (1.25 mg intravenous) + AVPA (0.5 mg)
Trial: 8017639
Drug: Intramuscular lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular lidocaine (control)